EP Wealth Advisors LLC Acquires Shares of 40,819 Boston Scientific Corporation $BSX

EP Wealth Advisors LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 40,819 shares of the medical equipment provider's stock, valued at approximately $1,742,000.

A number of other large investors also recently modified their holdings of BSX. Kelleher Financial Advisors bought a new stake in Boston Scientific during the 2nd quarter valued at $25,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter valued at about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the 4th quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific in the 1st quarter valued at about $28,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of the company's stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Royal Bank Of Canada decreased their price objective on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, July 30th. Daiwa Securities Group downgraded Boston Scientific from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 29th. Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Wolfe Research lowered shares of Boston Scientific from an "outperform" rating to a "peer perform" rating in a research report on Friday, May 29th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $71.62.

Boston Scientific Stock Up 2.1%

BSX stock opened at $50.39 on Friday. The stock has a market cap of $73.03 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.10 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock's fifty day simple moving average is $46.34 and its two-hundred day simple moving average is $57.86. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's board believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source